Get started
Author

Yuka Tanji

Observed names: Tanji Y, Tanji, Yuka, Yuka Saito Tanji, Yuka Saito-Tanji
Institution: Eli Lilly (Japan)
ORCID: 0000-0001-7850-1946
Observed ORCID: 0000-0001-7850-1946
OpenAlex ID: A5113944497
Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
2021 · Fumihiko Sakai, Takao Takeshima, et al. · Headache The Journal of Head and Face Pain · 44
PDF
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial
2024 · Mika Komori, Akichika Ozeki, et al. · The Journal of Headache and Pain · 26
PDF
Perceptions and impact of bipolar disorder in Japan: results of an Internet survey
2016 · Koichiro Watanabe, Eiji Harada, et al. · Neuropsychiatric Disease and Treatment · 19
PDF
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial
2023 · Mamoru Shibata, Atsuko Nihira, et al. · Neurology and Therapy · 10
PDF
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial
2022 · Yoichiro Hashimoto, Mika Komori, et al. · Expert Opinion on Drug Safety · 10
PDF
Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
2023 · Shigekazu Kitamura, Noboru Imai, et al. · Journal of Pain Research · 9
PDF
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial
2022 · Yasuhiko Matsumori, Mika Komori, et al. · Neurology and Therapy · 9
PDF
Safety profile of lasmiditan in patients with migraine in an Asian population
2022 · Koichi Hirata, Yasuhiko Matsumori, et al. · Expert Opinion on Drug Safety · 9
Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial
2022 · Takao Takeshima, Mika Komori, et al. · Advances in Therapy · 8
PDF
Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder
2016 · Yuka Saito-Tanji, Emi Tsujimoto, et al. · Case Reports in Psychiatry · 5
PDF
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study
2024 · Takao Takeshima, Hikaru Doi, et al. · Neurology and Therapy · 3
PDF
Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
2018 · Hideaki Katagiri, Masanori Taketsuna, et al. · Neuropsychiatric Disease and Treatment · 3
PDF
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
2018 · Hideaki Katagiri, Masanori Taketsuna, et al. · Neuropsychiatric Disease and Treatment · 2
PDF
Effectiveness of a Simple Individual Psychoeducation Program in a Patient with Bipolar II Disorder
2018 · Yuka Saito Tanji, Hisae Ono · Dual Diagnosis Open Access
PDF
Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
2018 · Katagiri H, Taketsuna M, et al. · Dove Medical Press (Taylor and Francis Group)
PDF
Works count: 23
Citation count: 157
H-index: 8
I10-index: 5
Year
Topic
Type